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Abstract
Earlier studies in this laboratory have shown the potential of artemisinin-curcumin combination therapy in experimental
malaria. In a parasite recrudescence model in mice infected with Plasmodium berghei (ANKA), a single dose of alpha,beta-
arteether (ART) with three oral doses of curcumin prevented recrudescence, providing almost 95% protection. The parasites
were completely cleared in blood with ART-alone (AE) or ART+curcumin (AC) treatments in the short-term, although the
clearance was faster in the latter case involving increased ROS generation. But, parasites in liver and spleen were not cleared
in AE or AC treatments, perhaps, serving as a reservoir for recrudescence. Parasitemia in blood reached up to 60% in AE-
treated mice during the recrudescence phase, leading to death of animals. A transient increase of up to 2–3% parasitemia
was observed in AC-treatment, leading to protection and reversal of splenomegaly. A striking increase in spleen mRNA
levels for TLR2, IL-10 and IgG-subclass antibodies but a decrease in those for INFc and IL-12 was observed in AC-treatment.
There was a striking increase in IL-10 and IgG subclass antibody levels but a decrease in INFc levels in sera leading to
protection against recrudescence. AC-treatment failed to protect against recrudescence in TLR22/2 and IL-102/2 animals. IL-
10 injection to AE-treated wild type mice and AC-treated TLR22/2 mice was able to prolong survival. Blood from the
recrudescence phase in AE-treatment, but not from AC-treatment, was able to reinfect and kill naı¨ve animals. Sera from the
recrudescence phase of AC-treated animals reacted with several parasite proteins compared to that from AE-treated
animals. It is proposed that activation of TLR2-mediated innate immune response leading to enhanced IL-10 production and
generation of anti-parasite antibodies contribute to protective immunity in AC-treated mice. These results indicate a
potential for curcumin-based combination therapy to be tested for prevention of recrudescence in falciparum and relapse in
vivax malaria.
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Introduction
The development of resistance to front-line antimalarial drugs
such as chloroquine and antifolates as well as decreased efficacy of
mefloquine and even quinine in malaria endemic regions has led to
introduction of artemisinin derivatives as the front line drug [1].
Although, artemisinins are particularly more active than any other
antimalarial, reducing the number of parasites by approximately 104
per cycle [2], they need to be taken for a seven-day period in
monotherapy for complete cure. The difficulty in adherence to this
regimen as well as use of suboptimal doses would result in
recrudescence and development of resistance and is a major concern
[3]. This has led to artemisinin derivatives (ART)-based combination
therapies in a three-day course regimen [4]. Among several
artemisinin derivatives-based combinations being used or tested,
artemether-lumefantrine and dihydroartemisinin-piperaquine com-
binations are considered as most promising [5], [6]. Our previous
studies indicated that curcumin from turmeric has antimalarial
activity [7]. Interestingly, curcumin was found to be very effective in
combination with ART in preventing parasite recrudescence in mice
infected with P. berghei (NK 65, non-cerebral strain) for 24 hr [8]. In
the mouse model used, arteether treatment alone (AE) was found to
result in parasite recrudescence, which was prevented by ART-
curcumin (AC) combination treatment. It was of interest to examine
the mode of action of AC combination treatment in this regard. The
results obtained indicate a unique mechanism of action for this
combination, suggesting its potential application to prevent
recrudescence/relapse in human falciparum and vivax malaria.
Results and Discussion
AC Treatment Cleared the Parasite Faster From Blood but
Not from Liver and Spleen
The mechanism of action of curcumin in the AC combination
treatment was investigated in the present study with mice infected
with P. berghei (ANKA) for 72 hr. Swiss mice were infected with P.
berghei and after 72 hr given a single injection of ART (750 mg,
i.m.) with or without 3 oral doses (5 mg per mouse) of curcumin at
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24 hr intervals. To get an accurate estimate of parasitemia, we
performed real time RT-PCR with specific primers for parasite
18S ribosomal RNA with RNA from blood [9] and a correlation
was established with parasitemia in blood as measured using smear
microscopy with Giemsa stain (Figure S1). A semi-quantitative
RT-PCR analysis of 18S rRNA with RNA from blood is provided
in Figure S2. Results of real time PCR analysis presented in
Figure 1A indicate that a parasitemia of around 35% was reached
Figure 1. Effect of AE and AC- treatments on parasitemia in mice infected with P.berghei for 72 hr. (A) Changes in parasite load in blood
at different time periods through real-time PCR analysis of parasite 18S rRNA after drug treatment. UT, untreated; C, curcumin, AE, ART alone; AC,
ART+CUR. D, died; N, not detectable. Data provided represent Mean 6 S.D. from three animals. The whole series was repeated thrice (total of 9
animals in each group) and number of animals surviving on day 30 in each group were as follows: UT, 0; C, 0; AE, 1; AC, 9. (B) Semiquantitative RT-PCR
analysis of parasite 18S rRNA in blood, liver and spleen on day 10 and 15 after infection. GAPDH was used as a control. *, positive control. (C) Effect of
injection of blood from recrudescing animals after AE and AC-treatments into naı¨ve animals. Five animals were used in each group.
doi:10.1371/journal.pone.0029442.g001
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in blood of P. berghei infected mice 4 days p.i. These levels
increased to around 60% on days 5 and 6 p.i., resulting in
mortality by day 5/6 p.i. After administration of one oral dose of
curcumin on day 3, the parasitemia transiently decreased to
around 15% on day 4 p.i. However, parasitemia increased with
the next two doses of curcumin and the animals died between 7
and 9 days p.i. AE and AC treatments resulted in parasitemias of
around 10% and 5% respectively on day 4 p.i. and 5% and 0%
respectively, on day 5 p.i. On day 6 p.i, no parasite could be
detected in blood in either treatment. Thus, parasite clearance in
AC treated mice was faster than that observed in mice treated with
AE alone. During the period of recrudescence, parasite load shot
up to around 57% and 58% on days 21 and 23 p.i. respectively, in
mice treated with AE alone and all these animals died during this
period. In contrast, a low level of parasitemia of around 3% was
seen on days 21 and 23 p.i. in AC-treated animals. However, these
parasites were soon cleared and no parasite could be detected in
blood on days 25 and 27 p.i. and all these animals survived. A
cumulative data of around 400 animals over the last over 4 years
indicate that in this recrudescence model, AE-treatment alone was
not effective and around 95% of the animals died, conversely AC
treatment resulted in close to 95% protection (Table S1).
Curcumin was effective only in conjunction with ART, as is also
evident from data on only a modest protection obtained with
curcumin in ART-resistant, self-clearing P. chabaudi-infected mice
[10]. However, recent studies have claimed that oral delivery of
curcumin bound to chitosan nanoparticles is able to completely
cure P.yeolli-infected mice [11].
A semi-quantitative RT-PCR analysis for 18 S rRNA indicated
that parasite RNA was undetectable in blood, but detectable in
liver and spleen on days 10 and 15 p.i. in both AE and AC treated
animals (Figure 1B). Thus, AE as well as AC treatments failed to
clear parasites in liver and spleen, indicating that these organs
could be the reservoir for recrudescence in blood. The survival of
rodent malaria merozoites in the lymphatic system was demon-
strated by Landau et al [12]. Recent studies by Wykes et al [13]
have shown that P.berghei can survive and replicate within CD317+
DCs and that a small percentage of these DCs release parasites
that can infect erythrocytes in naı¨ve mice. Since, a transient
parasitemia of 2 to 3% was seen in AC treatment during the
recrudescence phase (Figure 1A), blood from AE and AC- treated
animals in the recrudescence phase was injected into fresh
animals. The results indicated that while the parasites from the
AE treated animals infected and killed the recipients in 5 to 6 days,
blood from AC treated animals failed to do so even after several
days, indicating that the combination therapy had weakened the
parasite, rendering it incompetent to infect fresh cells (Figure 1C).
Curcumin Levels in Blood and Tissues
Curcumin levels were estimated in plasma, liver and spleen
using MALDI TOFF MS at different time intervals [14], [15].
Consistent values were obtained 4 hr after curcumin administra-
tion, and representative data are provided after the third oral dose.
The results presented in Table S2 indicate that the values ranged
between 2 to 4 mg per ml plasma or per g tissue. No curcumin or
its metabolites were detectable beyond 8 hr after curcumin
administration. Thus, curcumin has a half-life of only a few
hours. It is well established that ART derivatives have a half-life
ranging from 45 min to a few hours [3], [16].
AC Treatment Led to Enhanced Reactive Oxygen Species
(ROS) Generation in Infected Cells
A general principle in artemisinin-based combinations is that
the second drug should have a longer half-life to take care of the
residual parasite surviving after the elimination of the primary
drug [1], [2]. However, in the case of ART-curcumin combina-
tion, both the drugs are of short half life and therefore the
mechanisms involved in short-term and long-term effects needed
to be evaluated. Curcumin is known to be an anti-oxidant, but can
also manifest pro-oxidant activity in presence of metal ions [17].
Cui et al [18] have shown that curcumin enhances ROS
generation in P. falciparum cultures in the concentration range of
20 to 100 mM. Thus, it was of interest to examine the effect of AE
and AC treatments on the heme polymerization process giving rise
to hemozoin and ROS generation in the parasite. As shown in
Figure 2A, curcumin, AE and AC treatments inhibited hemozoin
levels, the combination showing maximum effect. While, the
inhibition in hemozoin content was more than 60% during the
period of experimentation, parasitemia decreased by 10–15%,
suggesting that accumulation of heme monomers could be the
earlier event. ROS generation was measured in infected blood
isolated 12 hr after a single injection of ART and one oral dose of
curcumin, by FACS analysis. The formation of intracellular ROS
in parasitized red blood cells was measured using 29,79-dichloro-
fluorescin diacetate (DCFH-DA, Sigma- Aldrich) essentially as
described by Cui et al [18]. DCFH-DA diffuses through the
membrane and is hydrolysed by intracellular esterases to DCFH
within the cells. DCFH is converted to DCF by the free radicals
and its fluorescence is measured by FACS analysis. The results
presented in Figure 2B and Table 1 indicate that all the treatments
increased mean fluorescent intensity and percent fluorescent cells,
with the combination showing maximum effect. These results
indicate that the earlier clearance of parasites in blood in AC
treatment is, perhaps, mediated by ROS generation in presence of
heme-iron.
AC treatment Reversed Splenomegaly in P.berghei-
infected Mice
RT-PCR data (Figure 1B) clearly indicate that the parasites
were not cleared from liver and spleen. Thus, the effect of AC
treatment in preventing recrudescence should involve a long-term
action of curcumin, mediated through an immune-priming effect.
Indication for such action came from the effect of drug treatments
on splenomegaly that accompanies malaria. The results presented
in Figure 3A indicate that there was a striking increase in spleen
weight soon after parasite infection, with a gradual fall with the
clearance of parasite load as a result of AE or AC treatment.
However, a dramatic increase in spleen weight was evident in AE-
treatment after day 14, attesting to parasite recrudescence. This
was completely prevented by AC treatment, with the spleen weight
tending towards that of uninfected mice.
Thus, it was of interest to look at the arms of innate and
adaptive immunity in this experimental set up. TOLL-like
receptors (TLRs) of the innate immune system recognize microbial
products, including those of protozoan parasites such as Plasmodium
and activate the development of acquired immune response. The
malarial parasite molecules containing pathogen-associated mo-
lecular-patterns (PAMPs) include glycophosphosphatidyl (GPI)
anchors and hemozoin with associated DNA, which are reported
to activate TLR2 and TLR9, respectively. The TLRs are
considered to be the central mediators in a pro-inflammatory
response in general in malaria, ultimately promoting antibody
production, B cell proliferation and T cell differentiation and
activation [19–21]. However, if the pro-inflammatory response is
excessive, over production of IFNc and TNFa may be detrimental
and an association with severe malaria has been shown [22], [23].
Regulatory cytokines such as IL-10 and TGFb are also produced
to suppress excessive proinflammatory responses in human and
Mechanism of Action of Curcumin-Based Combination
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experimental malaria [24–26]. Thus, self-clearing P. chaubadi AS
[27] and P. yoelii-infected [28] mouse models depict the protective
role of IFNc-dependent early innate and cell-mediated mecha-
nisms critical for control of acute stage infection and subsequent
antibody production for clearing the chronic phase. On the other
hand P. berghei ANKA infection in mice, considered as a model for
human P. falciparum malaria and used in the present study, leads to
excessive proinflammatory response and results in early death due
to cerebral malaria, requiring the production of regulatory
cytokines such as IL-10 to suppress the pro-inflammatory response
[24], [26]. Experiments were, therefore, carried out first of all to
quantify mRNA levels in spleen for relevant TLRs, pro- and anti-
inflammatory cytokines and IgG subclass antibodies. The results
presented in Figure 3B indicate that on day 14, AC treatment
resulted in a striking increase in TLR2-, but not TLR4- or TLR9-
mRNA levels. There was a significant increase in IL-10 mRNA
levels, but a decrease in INFc and IL-12 mRNA levels, compared
to AE treatment. TGFb mRNA levels did not show a change.
Interestingly, AC treatment led to an increase in almost all the IgG
subclass mRNA levels.
AC Treatment Supressed INFc but Enhanced IL-10 Levels
in Serum
We next examined whether spleen mRNA levels were reflected in
the serum levels of the cytokines during the course of the drug
treatments. The results presented in Figure 4A indicate that there was
an increase in both pro- and anti-inflammatory cytokine levels soon
after infection. AC treatment suppressed the pro-inflammatory
Figure 2. Effect of AE and AC-treatments on hemozoin content and ROS generation in P.berghei infected mice. (A). Hemozoin content in
parasite 8 hr and 12 hr after a single injection of ART and one oral dose of curcumin. The data represent Mean 6 S.D. from three animals. (B) FACS
analysis of P.berghi-infected red blood cells for ROS measurement 12 hr after drug treatment as per (A).
doi:10.1371/journal.pone.0029442.g002
Table 1. Mean fluorescent intensity and percent positive cells
in FACS analysis (Figure 2B).
Sample Mean fluorescent intensity % positive cells
Control 91.00611.21 2.0560.75
Curcumin 230.50622.56 13.9661.23
AE 207.82619.87 18.7261.98
AE+Curcumin 491.20631.25 42.4963.21
Data represent Mean 6 SD from three preparations.
doi:10.1371/journal.pone.0029442.t001
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cytokine IL-12 and IFNc levels. There was a striking increase in anti-
inflammatory cytokine IL-10 levels under these conditions, correlat-
ing with protection during the recrudescence phase. IL-10 injection to
AE-treated animals delayed the death of the animals (Figure 4B).
AC Treatment Was Not Protective in P.berghei-Infected
TLR22/2 and IL-102/2 Mice
It has been suggested that TLR2 agonists are specialized in
inducing IL-10 expression by antigen-presenting cells (APCs). This
has been shown with respect to macrophages and DCs stimulated
by antigens from mycobacterium, Yersinia and pneumococcal cell
wall [29]. If this were to be true in the present context, AC
treatment would fail in TLR22/2 animals. This study was carried
out in these knock out animals (C57BL/6) with and without IL-10
injection. It needs to be pointed out that C57BL/6 animals were
more sensitive to P. berghei-infection than Swiss mice and the
recrudescence in AE treatment started earlier, although the
protective effect of AC treatment was seen in this strain as well
(Figure 4C). The results presented in Figure 4D indicate that AC
treatment failed to protect in TLR-22/2 animals and IL-10
injection was able to delay the death of the animals. These results
also indicate that continuous production of IL-10 was essential for
maintaining the concentration of the cytokine to offer protection.
Finally, it is of interest to establish the role of IL-10 by examining
the protective efficacy of AC treatment in IL-102/2 animals. The
results presented in Figure 4E indicate that AC treatment delayed
death by a couple of days, but could not protect against
recrudescence in these animals. Thus, the role of IL-10 in
mediating the protective effect of curcumin against recrudescence
is clearly established. A previous report indicates that maintenance
of higher levels of IL-4 and IL-10 may be associated with
protection of BALB/c mice from early death compared to
C57BL/6 mice [26]. IL-10 has also been shown to play a crucial
role in the protection of experimental cerebral malaria due to P.
berghei ANKA strain by co-infection with non-lethal malaria
parasite [30]. The recovery of 40% of recrudescing P.berghei-
infected animals under conditions of the alkaloid manzamine A
treatment has also been shown to be correlated with increased IL-
10 levels in sera [31].
AC Treatment Enhanced Anti-parasite IgG Subclass
Levels in Serum
AC treatment resulted in a striking increase in anti-parasite
antibodies encompassing all IgG subclasses, contributing to
protective immunity during the recrudescence phase (Figure 5A).
At later periods of time, when the antibody titre waned,
anamnestic response was observed with fresh parasite injection
(Figure 5B). The animals were completely protected and mice are
known to be protected once cured of the malarial parasite
infection [32]. These results are also corroborated by Western blot
analysis, where sera from the recrudescence and later phases in
AC treated animals interacted with several parasite proteins,
compared to infected or AE-treated controls (Figure 5C).
Thus, quantification of TLR and cytokine mRNAs in the
spleen, assessment of cytokine and IgG subclass levels in serum,
response of TLR-22/2 and IL-102/2 animals with and without
IL-10 injection to AE and AC treatments have led us to conclude
that the immunomodulation brought about by AC treatment
involves activation of TLR-2, followed by production of IL-10 and
anti-parasite antibodies to prevent parasite recrudescence. IL-10
was initially described as a Th2 type cytokine, but subsequent
studies have shown that it is expressed by many cells in the
adaptive and innate immunity pathways, resulting in diverse
immunological responses, including Th1 and Th2 types [28].
While, the delineated pathway is, perhaps, the central mechanism
of action of curcumin in combination with ART, further studies
are needed to unravel the molecular interactions, interplay
between cytokines and the immune cells involved in memory
response. Although, curcumin is known to have a wide variety of
biochemical, pharmacological and immunological effects and is
being tested as a cure against a variety of diseases ranging from
Alzheimer [33], cystic fibrosis [34] to cancer in long-term studies
[35], the present study uniquely positions this molecule in a 3-day
therapy in combination with ART, to be tested against
recrudescence and relapse in falciparum and vivax malaria.
Primaquine, in a 14-day therapy, is the only anti-relapse drug
available against vivax malaria and hypnozoites are considered as
a hidden obstacle to malaria elimination [36]. In view of the
potent anti-inflammatory effect of curcumin its potential to be
Figure 3. Effect of AE and AC-treatments on changes in spleen mass and mRNA levels of cytokines, TLRs and IgG-sub-class
antibodies in P.berghei-infected mice. (A) Changes in spleen weight through out the course of infection and drug treatments. Data provided
represent Mean 6 S.D. from five animals. *, infected animals died 5/6 day (B) Semi-quantitative RT-PCR analysis of spleen RNA on day 14. UI,
unifected; I, infected; AE, ART alone; AC, ART+CUR.
doi:10.1371/journal.pone.0029442.g003
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Figure 4. Effect of AE and AC-treatments on changes in serum cytokine levels and survival response of TLR22/2 and IL-102/2 mice
to P.berghei-infection. (A) Changes in the serum levels of INFc, IL-10 and IL-12. The data represent Mean + S.D. from three sera preparations and
collected during day 6 (D6) to day 23 (D23) at intervals. The day 0 values correspond to those of uninfected animals. The values (pg/ml)
corresponding to infected animals, which all died on day 6, are as follows: INFc, 274622; IL-10, 422629; IL-12, 510639. The values corresponding to
infected animals treated with curcumin alone and which all died between, 7–8 days are as follows: INFc, 243622; IL-10, 310633; IL-12, 377639. (B)
Effect of IL-10 injection in AE-treated animals. IL-10 was injected on alternate days from day 10 in five doses ranging from 10 ng to 200 ng. Alternate
i.p. and i.v. routes were used. (C) Survival response of P.bergheiinfected C57BL/6 mice to AE and AC-treatments. The data are from two experiments
with five animals in each group. (D) Survival response of TLR2/2 animals with and without IL-10 injection (100 ng per animal for 5 days). (E) Survival
response of IL-102/2 animals. Four animals were used in each group for the experiments in (B), (D) and (E). The knock-out animals were in C57BL/6
background. While, the animals were injected with around 104 parasites in general, the IL 102/2 animals received around 103 parasites. UI, unifected;
I, infected; UT, untreated; C, curcumin; AE, ART alone; AC, ART+CUR.
doi:10.1371/journal.pone.0029442.g004
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Figure 5. Effect of AE and AC-treatments on changes in serum total IgG and IgG-subclass antibody levels and Western analysis of
parasite proteins with such sera in P.berghei-infected mice. Antibody levels were quantified in sera by ELISA using microtitre plates coated
with parasite lysate from day 6 (D6) onwards. (A) Changes in the serum levels of total IgG and IgG-subclass antibodies against parasite lysate. The
data represent Mean6 S.D. from three sera preparations (pooled from two animals each) and collected during day 6 (D6) to day 23 (D23) at intervals.
The day 0 values correspond to those of uninfected animals. The values (A405) corresponding to infected animals, which all died on day 6, are as
follows: IgG, 0.0760.002; IgG1, 0.0360.005; IgG2a, not detectable; IgG2b, not detectable; IgG3, not detectable; IgM, 0.2260.007. (B) Anamnestic
response of AC-treated animals. The animals were injected with fresh parasitized blood 10 days before the day mentioned in the Figure. The antibody
titre (IgG) was measured before and after challenge. The data represent an average from two sera preparations. (C) Western blot analysis of parasite
proteins with the different sera preparations. 1, uninfected; 2, day 5- infected; 3, AE -day 22; 4, AC day-22; 5 and 6, AC - day 75, before and after
challenge; 7 and 8; AC - day 180, before and after challenge.
doi:10.1371/journal.pone.0029442.g005
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tested as an adjunct therapy in cerebral malaria has also been
suggested [37], [38].
Materials and Methods
Treatment of mice
Animal experiments were carried out as per the guidelines of the
Committee for the Purpose of Control and Supervision of
Experimental Animals (CPCSEA), Government of India (Regis-
tration No: 48/1999/CPCSEA) and as approved by the
Institutional Animal Ethics Committee (IAEC) of the Indian
Institute of Science, Bangalore (CAF/Ethics/102/2007-435 and
CAF/Ethics/192/2010). The study was approved and supported
by the Department of Biotechnology, New Delhi (IDs: BT/
PR10541/Med/15/605/2008 and BT/01/10/MPB/DT).
All manipulations in mice were carried out under pentobarbital
anesthesia and all precautions undertaken to minimize suffering.
Mice (around 30 g) were injected intraperitoneally with P. berghei
(ANKA strain) – infected mouse blood (60–65% parasitemia) on
day 0 after appropriate dilution. The animals developed high
parasitemia and died between 5–6 days. The artemisinin
derivative a, b - arteether (ART) was injected intramuscularly
on day 3 at a dose of 750 mg/mouse (single injection). This was
followed by 3 oral doses of curcumin (CUR, 5 mg/mouse in
DMSO) given at 24 hr intervals.
Curcumin estimation in plasma
Extraction of curcuminoids from plasma was carried out as
described by Song et al [13]. Briefly, the plasma samples were
adjusted to pH 3.0 with 6N HCl and extracted twice with twice
the volume of a mixture of ethylacetate and isopropanol (9:1, v/v).
The ethylacetate layer was concentrated in a stream of nitrogen
and used for MALDITOFMS measurements as described for
curcumin estimation in mouse lung cell cultures [13]. Curcumin
concentration was calculated from a standard curve drawn in the
range 1 to 10 ng.
RT-PCR and Real Time PCR
Semi-quantitative RT-PCR was carried out for parasite 18S
ribosomal RNA with the following primer pair to obtain a 390 bp
PCR product: 59-AGGGATGTATTCGCTTTATTTAATGC-
39 and TCTTGTCCAAACAATTCATCATATC-39. The reac-
tion was carried out for 30 cycles as per the following regimen:
Denaturation at 95uC for 45 sec. annealing at 50uC for 40 sec.
and extension at 72uC for 40 sec, with a final extension for
10 min. The RT-PCR product was analysed by electrophoresis on
1% agarose gels. Total RNA was isolated from infected red blood
cells, liver and spleen by TRIZOL method (Invitrogen) followed
by DNAse I treatment. 1 mg of RNA was taken for RT reaction
(45uC for 60 min) using random hexamers (Pharmacia). A tenth of
the product was taken for PCR reaction. Parasite load was assessed
using Real Time PCR for 18S ribosomal RNA [9]. Real Time
PCR (ABI PrismH 7900 HT with SDS software version 2.1.1) was
carried out as per manufacturer’s protocol (Finnzymes-F-410L
DYNAmoTM HSSYBR Green a PCR Kit). 1.5 mg of RNA was
taken for RT reaction and different concentrations of cDNA were
taken for standardization. The primer pair designed to obtain a
143 bp PCR product was: 59-GTTAAAAGAATTGACGGAA-
GGGCACCACCAG-39 and 59-TGCATCACCATCCAAGAA-
ATCAAGAAAGAG-39. The Ct values were calculated for the
RNAs isolated from parasitized blood with different parasitemia
levels (assessed by Giemsa stain and counting parasitized cells in
different fields) and a correlation was established between Ct
values and parasitemia (Figure S1) and the results are expressed in
terms of the latter.
Semi-quantitative RT-PCR with standard primers was also
carried out with RNA isolated from spleen for the TLR-, cytokine-
and IgG sub-class mRNAs mentioned. A list of the primers used is
given in Table S3.
Measurement of intracellular ROS
For this purpose mice were infected with P. berghei for 72 hr and
then received a single injection of ART and one dose of curcumin
by oral feeding. Blood was collected 12 hr after drug treatment.
The formation of intracellular ROS in parasitized red blood cells
was measured using 29,79-dichlorofluorescin diacetate (DCFH-
DA, Sigma-Aldrich) essentially as described by Cui et al [18].
Briefly, 200 ml of blood was appropriately diluted with PBS and
100 ml was incubated in presence of DCFH-DA (5 mM) for 30 min
at 30uC. Excess DCFH-DA was removed by washing with PBS,
suspended in 1.5 ml PBS and 50 ml analysed by FACS using
caliber flow cytometer (Beckton Dickinson) equipped with an
excitation laser line at 488 nm and Cell Quest software (BD). The
parasitized and unparasitized erythrocytes were distinguished
during the flow cytometric analysis on the basis of fluorescence
intensity with the former and latter designated to different
quadrants. The DCFC green fluorescence was collected in a log
scale through a 530+20 band pass filter. For each analysis 10,000
events were recorded. Monoparametric histograms of the
fluorescence distribution were plotted for the estimation of ROS
production. The results are expressed in terms of % fluorescent
cells and mean fluorescent intensity.
Hemozoin estimation
For this purpose, mice were infected for 72 hr with P. berghei and
then received a single injection of ART and one oral dose of
curcumin. Blood was collected after 8 hr and 12 hr and parasites
were isolated from red blood cells after lysis with saponin.
Hemozoin content was estimated in the parasite as described by
Tripathi et al [39], who showed that multiple washing steps are
necessary to obtain hemozoin free of monomeric and bound
heme. Briefly, the parasite pellet was suspended in Tris-HCl buffer
containing 2.5% SDS and incubated at 37uC for 30 min and
centrifuged. The pellet was suspended in alkline-bicarbonate
buffer (100 mM, pH 9.2) and centrifuged. The final hemozoin
pellet was hydrolysed using IN NaOH: 2.5% SDS (1:9) and the
heme released measured at 405 nm.
Estimation of parasite-specific IgGs and cytokines in
serum
Soluble parasite proteins were prepared as described by Ang
et al [31]. The parasite pellet was suspended in an appropriate
volume of PBS followed by sonication (5 min at 4uC) and
centrifugation at 10,000 g for 10 min. The supernatant was stored
at 280uC and used to estimate parasite – specific IgGs by ELISA.
10 ml of the supernatant was coated onto 96-well ELISA plates
(4uC overnight) and reacted with 1:10 diluted serum in a total
volume of 100 ml. After carrying out the blocking and washing
steps, 50 ml of secondary goat anti-mouse IgG-peroxidase
conjugate (Genei TM) at 1:3000 dilution was added per well
and color developed with ABTS substrate was measured at
405 nm using an ELISA plate reader. IgG sub-class antibodies
were obtained from Santa Cruz Biotechnology, Inc, USA. INF-c,
IL-10 and IL-12 were all measured in 10 ml of mouse serum using
Murine ELISA Development Kits from PEPROTECH Asia
(Israel) as per the manufacturer’s protocol. Biotinylated Detection
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Antibody and Avidin-HRP conjugate were used with ABTS liquid
substrate to give a colored product measured at 405 nm. The sera
were also used to check for antibodies against total parasite
proteins by Western blot analysis. For this purpose, the parasite
pellet was suspended in SDS-buffer and 40 mg protein was
analysed on SDS-PAGE (10% polyacrylamide) followed by
Western analysis with different sera.
Experiments with Knock Out animals
TLR-22/2and IL-102/2 mice in C57BL/6 background were
the kind gifts from Prof. Ruslan Medzhitov (Yale University
School of Medicine, New Haven, USA). These animals are
subsequently being maintained in a specific pathogen free animal
facility at International Centre for Genetic Engineering and
Biotechnology, New Delhi. The protocols for infection and drug
treatment were the same as for the Swiss mice described earlier,
except that while around 104 parasites were injected in the case of
wild-type (Swiss) mice and TLR22/2 (C57BL/6) animals, the
IL102/2 (C57BL/6) animals received around 103 parasites. This
resulted in a slightly longer survival period for the latter, but AC
could not protect even under these conditions. In view of the
paucity of IL 102/2 animals, IL 10 injected group was not
included. Four animals were used in each group.
Statistics
Long-term experiments (Figures 1A, 4A and 5A) were repeated
thrice and 3 animals were used per group in each experiment. The
data represent Mean 6 S.D. from 3 animals in one such series.
The results obtained in the repetitive experiments are very similar,
except that the responses varied by 1–3 days between the series.
All other data are from experiments with 4 or 5 animals in each
group. Sera were pooled from two mice for each measurement.
Significance between control and treated group was examined
using Student’s t test and values of P,0.05 are considered as
significant.
Supporting Information
Figure S1 Correlation between Real-Time PCR of parasite 18S
rRNA (Ct values) and parasitemia. RNA was isolated from the
parasite and Real-Time PCR for 18S rRNA was carried out at
different parasitemia values ranging from 5% to 70% as quantified
using Giemsa stained blood smears.
(TIF)
Figure S2 Semi-quantitative RT-PCR analysis for parasite 18S
rRNA with RNA from blood of P. berghei-infected mice. UT,
untreated; C, curcumin; AE, ART alone; AC, ART+CUR.
GAPDH -RNA was used as loading control.
(TIF)
Table S1 Comparative effects of AE and AC Treatments on the
survival of P. berghei-infected mice. The data provided are from 20
experiments carried over a period of 4 years. The animals were
infected with P. berghei for 72 hr and then given a single injection of
ART (AE), followed by three oral doses of curcumin (AC) at 24 hr
intervals. The experimental details are given in the main paper.
(DOC)
Table S2 Curcumin (C) and Demethoxy Curcumin (DC)
concentrations in mice tissues. Data represent Mean 6 SD from
three preparations. *mg/ml; #mg/g; ND: not detectable.
(DOC)
Table S3 Primers used for semi-quantitative RT-PCR analysis
of RNA from spleen. Primers were designed for the IgG sub-class
antibodies and unique forward primers and a common reverse
primer were used. The products obtained were verified and
characterized based on unique restriction sites. Standard primers
were used in other cases.
(DOC)
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